仑伐替尼治疗肝细胞癌的研究进展

摘要/Abstract

摘要： 肝细胞癌是影响全球健康的重大挑战,已成为我国乃至世界较为常见的肿瘤致死原因。由于肝细胞癌具有隐匿性强、病程进展快、恶性程度高的特点,很多患者在就诊时就已失去手术机会。仑伐替尼具有抑制肿瘤细胞生长、抑制肿瘤血管生成的作用,对不可切除的肝细胞癌患者具有较好疗效,明显延长了患者生存时间,目前已成为治疗不可切除肝细胞癌的一线靶向药物。同时仑伐替尼参与联合治疗肝细胞癌也有积极的治疗效果,在肝细胞癌联合治疗中具有良好的临床应用前景。本文就仑伐替尼治疗肝细胞癌的研究现状进行系统性综述,并对未来该药物的应用前景进行展望。

关键词: 肝细胞癌, 仑伐替尼, 分子靶向治疗

Abstract: Hepatocellular carcinoma is a major challenge affecting global health and has been recognised as a leading cause of death both in China and the world. Due to its insidious, rapidly progressive and highly malignant nature, many patients with hepatocellular carcinoma have already lost their chance of surgery by the time they are diagnosed. Lenvatinib has the ability to inhibit the growth of both tumor cells and tumor angiogenesis, which results in a better effect on patients with unresectable hepatocellular carcinoma and significantly prolongs the overall survival of patients. Therefore, lenvatinib is considered as a first-line target drug for the treatment of unresectable hepatocellular carcinoma. This article presents a systematic review about the research progress of lenvatinib for hepatocellular carcinoma and future perspectives.

Key words: Hepatocellular carcinoma, Lenvatinib, Molecularly targeted therapy

裴玺睿, 李晓航. 仑伐替尼治疗肝细胞癌的研究进展[J]. 肝癌电子杂志, 2024, 11(1): 25-29.

Pei Xirui, Li Xiaohang. Research progress of lenvatinib for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2024, 11(1): 25-29.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] LLOVET J M, KELLEY R K, VILLANUEVA A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
[3] FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[4] MEJIA J C, PASKO J.Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma[J]. Surg Clin North Am, 2020, 100(3): 535-549.
[5] CHEN L T, MARTINELLI E, CHENG A L, et al.Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO[J]. Ann Oncol, 2020, 31(3): 334-351.
[6] SU G L, ALTAYAR O, O’SHEA R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma[J]. Gastroenterology, 2022, 162(3): 920-934.
[7] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. ELECTRONIC ADDRESS: EASLOFFICE@EASLOFFICE.EU, EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[8] LEE Y T, TAN Y J, OON C E.Molecular targeted therapy: treating cancer with specificity[J]. Eur J Pharmacol, 2018, 834: 188-196.
[9] LABRIE M, BRUGGE J S, MILLS G B, et al.Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer[J]. Nat Rev Cancer, 2022, 22(6): 323-339.
[10] ZHAO Y, ZHANG Y N, WANG K T, et al.Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(1): 188391.
[11] PATEL S A, NILSSON M B, LE X, et al.Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy[J]. Clin Cancer Res, 2023, 29(1): 30-39.
[12] CARMELIET P.VEGF as a key mediator of angiogenesis in cancer[J]. Oncology, 2005, 69(Suppl 3): 4-10.
[13] SARKAR C, CHAKROBORTY D, GOSWAMI S, et al. VEGF-A controls the expression of its regulator of angiogenic functions, dopamine D2 receptor, on endothelial cells[J]. J Cell Sci, 2022, 135(11): jcs259617.
[14] MA L, HERNANDEZ M O, ZHAO Y, et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer[J]. Cancer Cell, 2019, 36(4): 418-430.e6.
[15] BALUK P, HASHIZUME H, MCDONALD D M.Cellular abnormalities of blood vessels as targets in cancer[J]. Cur Opin Genet Develop, 2005, 15(1): 102-111.
[16] MENG Y M, JIANG X, ZHAO X, et al.Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities[J]. Nat Commun, 2021, 12(1): 6011.
[17] AL-SALAMA Z T, SYED Y Y, SCOTT L J. Lenvatinib: a review in hepatocellular carcinoma[J]. Drugs, 2019, 79(6): 665-674.
[18] YAMAMOTO Y, MATSUI J, MATSUSHIMA T, et al.Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage[J]. Vasc Cell, 2014, 6: 18.
[19] HIRATA E, GIROTTI M R, VIROS A, et al.Intravital imaging reveals how braf inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling[J]. Cancer Cell, 2015, 27(4): 574-588.
[20] LIN B C, WANG M, BLACKMORE C, et al.Liver-specific activities of FGF19 require klotho beta[J]. J Biol Chem, 2007, 282(37): 27277-27284.
[21] PRIETO-DOMINGUEZ N, SHULL A Y, TENG Y.Making way for suppressing the FGF19/FGFR4 axis in cancer[J]. Future Med Chem, 2018, 10(20): 2457-2469.
[22] RAJA A, PARK I, HAQ F, et al.FGF19-FGFR4 signaling in hepatocellular carcinoma[J]. Cells, 2019, 8(6): 536.
[23] PHAN P, SAIKIA B B, SONNAILA S, et al.The saga of endocrine FGFs[J]. Cells, 2021, 10(9): 2418.
[24] LI X.The FGF metabolic axis[J]. Front Med, 2019, 13(5): 511-530.
[25] JOHANSSON H, SØNDERGAARD J N, JORNS C, et al. Chenodeoxycholic acid modulates bile acid synthesis independent of fibroblast growth factor 19 in primary human hepatocytes[J]. Front Endocrinol, 2021, 11: 554922.
[26] ZHANG K, CHU K, WU X, et al.Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma[J]. Cancer Research, 2013, 73(4): 1298-1307.
[27] OKAMOTO K, IKEMORI-KAWADA M, JESTEL A, et al.Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization[J]. ACS Med Chem Lett, 2015, 6(1): 89-94.
[28] MATSUKI M, HOSHI T, YAMAMOTO Y, et al.Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models[J]. Cancer Med, 2018, 7(6): 2641-2653.
[29] IKEDA K, KUDO M, KAWAZOE S, et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J]. J Gastroenterol, 2017, 52(4): 512-519.
[30] CHOI N R, KIM J Y, HONG J H, et al.Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis[J]. BMC Gastroenterol, 2022, 22(1): 135.
[31] KUDO M, FINN R S, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[32] IWATA H, IMAMURA S, HORI A, et al.Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism[J]. Biochemistry, 2011, 50(5): 738-751.
[33] TANG W, CHEN Z, ZHANG W, et al.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects[J]. Signal Transduct Target Ther, 2020, 5(1): 87 .
[34] SASAKI R, KANDA T, FUJISAWA M, et al.Different mechanisms of action of regorafenib and lenvatinib on Toll-like receptor-signaling pathways in human hepatoma cell lines[J]. Int J Mol Sci, 2020, 21(9): 3349.
[35] ZOU W, WOLCHOK J D, CHEN L. PD-L1 (B7-H1) andPD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers,combinations[J]. Sci Transl Med, 2016, 8(328): 328rv4.
[36] WU Q.Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway[J]. Acta Pharmacol Sin, 2021, 42(1): 1-9.
[37] CHEN G, HUANG A C, ZHANG W, et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560(7718): 382-386.
[38] KIMURA T, KATO Y, OZAWA Y, et al.Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model[J]. Cancer Sci, 2018, 109(12): 3993-4002.
[39] TORRENS L, MONTIRONI C, PUIGVEHÍ M, et al.Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma[J]. Hepatology, 2021, 74(5): 2652-2669.
[40] YI C, CHEN L, LIN Z, et al.Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death‐1 in HCC[J]. Hepatology, 2021, 74(5): 2544-2560.
[41] LI Q, CAO M, YUAN G, et al.Lenvatinib plus camrelizumab vs. lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study[J]. Front Oncol, 2022, 12: 809709.
[42] FINN R S, IKEDA M, ZHU A X, et al.Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[43] XU Y, FU S, SHANG K, et al.PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib[J]. Front Oncol, 2022, 12: 958869.
[44] LEE C H, SHAH A Y, RASCO D, et al.Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111/KEYNOTE-146): a phase 1b/2 study[J]. Lancet Oncol, 2021, 22(7): 946-958.
[45] MAKKER V, COLOMBO N, CASADO HERRÁEZ A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer[J]. N Engl J Mede, 2022, 386(5): 437-448.
[46] ARANCE A, DE LA CRUZ-MERINO L, PETRELLA T M, et al. Phase Ⅱ LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination[J]. J Clin Oncol, 2023, 41(1): 75-85.
[47] RAOUL J L, FORNER A, BOLONDI L, et al.Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence[J]. Cancer Treat Rev, 2019, 72: 28-36.
[48] KUDO M.A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE[J]. Liver Cancer, 2019, 8(5): 299-311.
[49] CHANG Y, JEONG S W, YOUNG JANG J, et al.Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21): 8165.
[50] HATANAKA T, YATA Y, NAGANUMA A, et al.Treatment strategy for intermediate-stage hepatocellular carcinoma: transarterial chemoembolization, systemic therapy, and conversion therapy[J]. Cancers, 2023, 15(6): 1798.
[51] FU Z, LI X, ZHONG J, et al.Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study[J]. Hepatol Int, 2021, 15(3): 663-675.
[52] LYU N, WANG X, LI J B, et al.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phaseⅢ trial (FOHAIC-1)[J]. J Clin Oncol, 2022, 40(5): 468-480.
[53] LAI Z, HUANG Y, WEN D, et al.One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma[J]. BMC Med, 2022, 20(1): 415.
[54] ZHENG K, ZHU X, FU S, et al.Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial[J]. Radiology, 2022, 303(2): 455-464.
[55] JIN H, WANG L, BERNARDS R.Rational combinations of targeted cancer therapies: background, advances and challenges[J]. Nat Rev Drug Discov, 2023, 22(3): 213-234.
[56] LONG F, CHEN S, LI R, et al.Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma[J]. Med Oncol, 2023, 40(5): 147.
[57] IWAMOTO H, SHIMOSE S, SHIRONO T, et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity[J]. Clin Mol Hepatol, 2023, 29(3): 593-604.
[58] DENG H, KAN A, LYU N, et al.Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma[J]. Liver Cancer, 2020, 9(3): 338-357.
[59] SUN L, XU X, MENG F, et al.Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a review[J]. Front Oncol, 2022, 12: 980214.
[60] CHEN S, WU Z, SHI F, et al.Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study[J]. J Cancer Res Clin Oncol, 2022, 148(8): 2115-2125.
[61] WANG J, XUE Y, LIU R, et al.DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study[J]. Front Bioeng Biotechnol, 2023, 10: 1112500.
[62] BARGELLINI I, LORENZONI V, LORENZONI G, et al.Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis[J]. Eur Radiol, 2021, 31(10): 7512-7522.
[63] VOGL T J, LAHRSOW M.The role of conventional TACE (cTACE) and DEBIRI-TACE in colorectal cancer liver metastases[J]. Cancers(Basel), 2022, 14(6): 1503.
[64] WU S J, RUAN D D, WU Q Y, et al.Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with lenvatinib and Anti-PD-1 antibodies for unresectable hepatocellular carcinoma: a retrospective analysis[J]. J Hepatocell Carcinoma, 2023, 10: 807-820.
[65] DHONDT E, LAMBERT B, HERMIE L, et al.90 Y Radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phaseⅡ randomized controlled trial[J]. Radiology, 2022, 303(3): 699-710.
[66] LIU J, LI Z, ZHANG W, et al.Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients[J]. Front Pharmacol, 2021, 12: 709060.
[67] LLOVET J M, VOGEL A, MADOFF D C, et al.Randomized Phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. Cardiovascu Intervent Radiol, 2022, 45(4): 405-412.
[68] CAO F, YANG Y, SI T, et al.The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study[J]. Front Oncol, 2021, 11: 783480.
[69] WENG Y S, CHIANG I T, TSAI J J, et al.Lenvatinib synergistically promotes radiation therapy in hepatocellular carcinoma by inhibiting Src/STAT3/NF-κB-mediated epithelial-mesenchymal transition and metastasis[J]. Int J Radiat Oncol Biol Phys, 2023, 115(3): 719-732.
[70] GUPTA R, KADHIM M M, TURKI JALIL A, et al.Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches[J]. Environ Res, 2023, 228: 115767.
[71] UNE N, TAKANO-KASUYA M, KITAMURA N, et al.The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors[J]. Med Oncol, 2021, 38(6): 60.
[72] JI X, XU Z, SUN J, et al.Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study[J]. Radiat Oncol, 2023, 18(1): 101.
[73] LI G, SHU B, ZHENG Z, et al.Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial[J]. Front Oncol, 2022, 12: 1051916.